UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, DC 20549
FORM 8-K
CURRENT REPORT PURSUANT
TO SECTION 13 OR 15(D) OF THE
SECURITIES EXCHANGE ACT OF 1934
Date of report (Date of earliest event reported): May 17, 2005
Impax Laboratories, Inc.
- --------------------------------------------------------------------------------
(Exact Name of Registrant as Specified in Its Charter)
Delaware 0-27354 65-0403311
- -----------------------------------------------------------------------------------------------------------
(State or other jurisdiction (Commission File Number) (IRS Employer Identification No.)
of incorporation)
30831 Huntwood Ave., Hayward, CA 94544
- -----------------------------------------------------------------------------------------------------------
(Address of principal executive offices) (Zip Code)
Registrant's telephone number, including area code (510) 476-2000
----------------
Not Applicable
- --------------------------------------------------------------------------------
(Former name or former address, if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended to
simultaneously satisfy the filing obligation of the registrant under any of the
following provisions (see General Instruction A.2. below):
|_| Written communications pursuant to Rule 425 under the Securities Act
(17 CFR 230.425)
|_| Soliciting material pursuant to Rule 14a-12 under the Exchange Act
(17 CFR 240.14a-12)
|_| Pre-commencement communications pursuant to Rule 14d-2(b) under the
Exchange Act (17 CFR 240.14d-2(b))
|_| Pre-commencement communications pursuant to Rule 13e-4(c) under the
Exchange Act (17 CFR 240.13e-4(c))
ITEM 5.02. DEPARTURE OF DIRECTORS OR PRINCIPAL OFFICERS; ELECTION OF DIRECTORS;
APPOINTMENT OF PRINCIPAL OFFICERS.
5.02(b) As previously reported in a Current Report on Form 8-K dated February
22, 2005, David Edwards, a current director of the Company, informed the
Company's Board of Directors that he would not stand for reelection at the
Company's next Annual Meeting of Stockholders in order to devote more time to
personal and business interests.
Mr. Edwards informed the Company on May 17, 2005 that, because the
Company is holding the 2005 Annual Meeting of Stockholders later than usual, his
personal and professional commitments would require him to resign as a director
prior to the Annual Meeting. He resigned effective May 17, 2005. There were no
disagreements between Mr. Edwards and the Company or its management.
2
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the
registrant has duly caused this report to be signed on its behalf by the
undersigned hereunto duly authorized.
IMPAX LABORATORIES, INC.
Date: May 18, 2005 By: /s/ Barry R. Edwards
------------------------------
Name: Barry R. Edwards
Title: Chief Executive Officer
3